In the GetGoal-L- Asia and -S trials type 2 diabetes patients were treated with different anti-diabetic drugs (i.e., different basal insulins, metformin, sulfonylureas) at different dosages in combination with lixisenatide or placebo [10, 11]. This evidence concerns the gene INS and type 2 diabetes mellitus.